Cardiff Oncology Investor Relations Material
Latest events
Study Update
Cardiff Oncology
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Cardiff Oncology Inc
Access all reports
Cardiff Oncology Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing innovative therapies for various cancers. The company's primary approach involves leveraging PLK1 (Polo-like Kinase 1) inhibition to create novel cancer treatments. Their flagship product, onvansertib, is an oral selective PLK1 inhibitor currently being evaluated in combination with standard-of-care therapeutics across several clinical programs. These include treatments for KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.
Key slides for Cardiff Oncology Inc
Study Update
Cardiff Oncology Inc
Study Update
Cardiff Oncology Inc
Latest articles
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
Ticker symbol
CRDF
Country
🇺🇸 United States